Karyopharm Therapeutics (KPTI) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 46.2% versus a loss of 89.8%. Over five years, KTTA leads with a -99.3% price change compared with -99.3% for KPTI. Pasithea Therapeutics is the larger company by market cap ($15.6 million vs $13.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KPTI | KTTA |
|---|---|---|
| Share price | $0.605 | $0.4675 |
| Market cap | $13.72M | $15.62M |
| 1-day change | +0.83% | +6.03% |
| YTD return | -91.85% | -65.82% |
| 1-year return | -89.83% | -46.23% |
| 5-year return | -99.28% | -99.26% |
| EPS (TTM) | $-14.33 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.99 | $2.06 |
| 52-week low | $0.5652 | $0.281 |
| Distance from 52-week high | -94.49% | -77.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +1098.35% | +541.71% |
| Average volume | 1.71M | 225.69K |
| Shares outstanding | 22.68M | 33.41M |
| Employees | 228 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed KPTI by 43.6 percentage points over the past year.
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Health Care · Biotechnology: Pharmaceutical Preparations · 228 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
KPTI vs KTTA FAQ
Which is bigger, Karyopharm Therapeutics or Pasithea Therapeutics?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $15.62M compared with $13.72M for Karyopharm Therapeutics (KPTI).
Which stock has performed better over the past year, KPTI or KTTA?
KTTA returned -46.23% over the past 12 months, compared with -89.83% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are Karyopharm Therapeutics and Pasithea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.